Patterson Companies, Inc.

Patterson reported fiscal Q2 2025 consolidated sales of $1.67 billion, up 1.3% year over year, with internal sales up 0.6%. GAAP gross margin was 19.6% versus 20.5% a year ago, and adjusted gross margin was 20.0% versus 20.6%; adjusted operating margin was 3.6% versus 4.2%. Reported EPS was $0.30 versus $0.42, and adjusted EPS was $0.47 versus $0.50. By segment, Dental internal sales declined 2.3% and Animal Health internal sales increased 1.9%; Dental adjusted operating margin was 8.3% and Animal Health adjusted operating margin was 3.9%. For full-year fiscal 2025, management lowered GAAP EPS guidance to $1.83-$1.93 and adjusted EPS guidance to $2.25-$2.35.

Don Zurbay said the quarter was mixed because Animal Health performed well but Dental remained under pressure from softer equipment spending and the lingering Change Healthcare disruption. He emphasized that Patterson is rightsizing its organization, preserving customer-facing roles, and still investing in software, value-added services, and acquisitions to support long-term growth. His tone was cautious but confident that the company can keep gaining share and improve over time as the macro environment stabilizes.

Kevin Barry highlighted the specific financial drivers behind the quarter: higher revenue was offset by lower Dental equipment and software-related volume, which weighed on gross margin and operating margin. He said the company improved free cash flow by $41.5 million in the first six months, helped by disciplined inventory management and lower CapEx, and returned $96.2 million to shareholders year to date through dividends and repurchases. He also pointed to the $16 million annualized cost savings from the Q2 restructuring and said back-half margins should benefit from cost actions, mix, and lower interest expense.

Analysts focused on how much of the lowered guidance was macro-driven versus under management’s control, and management pointed to persistent Dental weakness plus the lingering Change Healthcare drag, offset by cost cuts and better execution in Animal Health. Several questions centered on whether the $16 million cost savings would show up quickly; Don said there was some Q2 benefit but the main impact comes in the second half. Analysts also asked about dental consumables, equipment, strategic alternatives, and the Dentsply Sirona relationship; management said consumables look flat to slightly down, equipment remains weak until rates and innovation improve, and the supplier relationship is being worked through with a shared goal of mutual success.